Maurice Enriquez-Sarano

Maurice Enriquez-Sarano

Auto-generated profile, based on publicly available information

Maurice Enriquez-Sarano

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2021 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
SCSean Coffey
Sean Coffey
RRRoss Roberts-Thomson
Ross Roberts-Thomson
ABAlex Brown
Alex Brown
JCJonathan Carapetis
Jonathan Carapetis
MCMao Chen
Mao Chen
BPBernard Prendergast
Bernard Prendergast

22 March 2021 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
MCMichal Cohen-Shelly
Michal Cohen-Shelly
ZAZachi I Attia
Zachi I Attia
PFPaul A Friedman
Paul A Friedman
SISaki Ito
Saki Ito
BEBenjamin A Essayagh
Benjamin A Essayagh
JOJae K Oh
Jae K Oh
Aims : Early detection of aortic stenosis (AS) is becoming increasingly important with a better outcome after aortic valve replacement in asymptomatic severe AS patients and a poor outcome in moderate AS. We aimed to develop artificial intelligence-enabled electrocardiogram (AI-ECG) using a convolutional neural network to identify patients with moderate to severe AS. Methods and results : Between 1989 and 2019, 258 607 adults [mean age 63 ± 16.3 years; women 122 790 (48%)] with an echocardiography and an ECG performed within 180 days were identified from the Mayo Clinic database. Moderate to severe AS by echocardiography was present in 9723 (3.7%) patients. Artificial intelligence training was performed in 129 788 (50%), validation in 25 893 (10%), and testing in 102 926 (40%) randomly selected subjects. In the test group, the AI-ECG labelled 3833 (3.7%) patients as positive with the area under the curve (AUC) of 0.85. The sensitivity, specificity, and accuracy were 78%, 74%, and 74%, respectively. The sensitivity increased and the specificity decreased as age increased. Women had lower sensitivity but higher specificity compared with men at any age groups. The model performance increased when age and sex were added to the model (AUC 0.87), which further increased to 0.90 in patients without hypertension. Patients with false-positive AI-ECGs had twice the risk for developing moderate or severe AS in 15 years compared with true negative AI-ECGs (hazard ratio 2.18, 95% confidence interval 1.90–2.50). Conclusion : An AI-ECG can identify patients with moderate or severe AS and may serve as a powerful screening tool for AS in the community.

11 August 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
ASAvi Sabbag
Avi Sabbag
BEBenjamin Essayagh
Benjamin Essayagh
JBJuan David Ramírez Barrera
Juan David Ramírez Barrera
CBCristina Basso
Cristina Basso
ABAna Berni
Ana Berni
PLPatrizio Lancellotti
Patrizio Lancellotti
Risk stratification scheme. Risk stratification aiming at assessing the risk of VAs and SCD in patients with MVP, involving two phases based on the clinical and imaging context and the uncovered arrhythmia. In the absence of ventricular tachycardia, phenotypic risk features will trigger the intensity of screening for arrhythmia. Green boxes indicate green heart consensus statements and yellow boxes indicate yellow heart consensus statements. High risk - sustained VT, polymorphic NSVT, fast (>180 bpm) NSVT, VT/NSVT resulting in syncope. ICD = implantable cardioverter defibrillator; LA = left atrium; LGE = late gadolinium enhancement; LV-EF = left ventricular ejection fraction; MAD = mitral annular disjunction; MV = mitral valve; PVCs = premature ventricular contractions; TWI = T-wave inversion; VT = ventricular tachycardia. #Additional ECG monitoring method may be used such as loop recorders.

1 August 2020 in JACC
Verified
Journal Article
Closed access
BEBenjamin Essayagh
Benjamin Essayagh
ASAvi Sabbag
Avi Sabbag
CAClémence Antoine
Clémence Antoine
GBGiovanni Benfari
Giovanni Benfari
LYLi-Tan Yang
Li-Tan Yang
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano

9 August 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
MFMiho Fukui
Miho Fukui
VBVinayak N. Bapat
Vinayak N. Bapat
SGSantiago Garcia
Santiago Garcia
MDMarshall W. Dworak
Marshall W. Dworak
GHGo Hashimoto
Go Hashimoto
PSPaul Sorajja
Paul Sorajja
Background: Although transcatheter aortic valve replacement (TAVR) therapy continues to grow, there have been concerns about the occurrence of hypoattenuating leaflet thickening (HALT), which may affect prosthesis function or durability. This study aimed to examine prosthesis frame factors and correlate their extent to the frequency of HALT and clinical outcomes. Methods: We prospectively examined 565 patients with cardiac computed tomography screening for HALT at 30 days after balloon-expandable SAPIEN3 and self-expanding EVOLUT TAVR. Deformation of the TAVR prostheses, asymmetric prosthesis leaflet expansion, prosthesis sinus volumes, and commissural alignment were analyzed on the postprocedural computed tomography. For descriptive purposes, an index of prosthesis deformation was calculated, with values >1.00 representing relative midsegment underexpansion. A time-to-event model was performed to evaluate the association of HALT with the clinical outcome. Results: Overall, HALT was present in 21% of SAPIEN3 patients and in 16% of EVOLUT patients at 30 days after TAVR. The occurrence of HALT was directly associated with greater prosthesis frame deformation ( P <0.001), worse asymmetry of the leaflets ( P <0.001), and smaller TAVR neosinus volumes ( P <0.001). These relations were present in both prosthetic types and in all of their size ranges (all P <0.05). In multivariable analyses that include clinical variables previously associated with HALT (eg, anticoagulant therapy), variables of TAVR prosthesis deformation remained predictive of HALT. Although HALT was not associated with changes in prosthetic hemodynamics, its presence was associated with the risk of mortality at 1 year, with respect to greater incidences of all-cause mortality (hazard ratio, 2.98 [95% CI, 1.57–5.63]; P =0.001), cardiac death (hazard ratio, 4.58 [95% CI, 1.81–11.6]; P =0.001), and a composite outcome of all-cause mortality and heart failure hospitalization (hazard ratio, 1.94 [95% CI, 1.14–3.30]; P =0.02) with adjustment for age, sex, and comorbidities. Conclusions: Nonuniform expansion of TAVR prostheses resulting in frame deformation, asymmetric leaflet, and smaller neosinus volume is related to occurrence of HALT in patients who undergo TAVR. These data may have implications for both prosthesis valve design and deployment techniques to improve clinical outcomes for these patients.

22 July 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
HMHector I Michelena
Hector I Michelena
Alessandro Della CorteAlessandro Della Corte
Alessandro Della Corte
AEArturo Evangelista
Arturo Evangelista
JMJoseph J Maleszewski
Joseph J Maleszewski
WEWilliam D Edwards
William D Edwards
HSHans-Joachim Schäfers
Hans-Joachim Schäfers
This International Consensus Classification and Nomenclature for the congenital bicuspid aortic valve condition recognizes 3 types of bicuspid valves: 1. The fused type (right-left cusp fusion, right-non-coronary cusp fusion and left-non-coronary cusp fusion phenotypes); 2. The 2-sinus type (latero-lateral and antero-posterior phenotypes); and 3. The partial-fusion (forme fruste) type. The presence of raphe and the symmetry of the fused type phenotypes are critical aspects to describe. The International Consensus also recognizes 3 types of bicuspid valve-associated aortopathy: 1. The ascending phenotype; 2. The root phenotype; and 3. Extended phenotypes.